Pancreatic Cancer Risk Rises with Fasting Glucose
By LabMedica International staff writers Posted on 15 Aug 2019 |
Image: A histopathology of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, arising in the pancreas head region (Photo courtesy of KGH).
More than 56,000 Americans are expected to be diagnosed with pancreatic cancer in 2019, which is more than 150 people diagnosed every day. Pancreatic cancer is the ninth most commonly diagnosed cancer in women and the 10th most commonly diagnosed in men in the USA.
The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It makes enzymes that help digestion and hormones that control blood-sugar levels. Pancreatic cancer’s exact causes are not well understood. About 5% to 10% of pancreatic cancers are considered familial or hereditary. Most pancreatic cancer happens randomly or is caused by things such as smoking, obesity and age.
A team of scientists associated with Kangbuk Samsung Hospital (Seoul, Korea) analyzed data from 25.4 million patients who participated in a health examination between 2009 and 2013, using data from the National Health Insurance Service. They evaluated pancreatic cancer incidence rates according to fasting glucose level. Cumulative incidence rate for pancreatic cancer was calculated after grouping patients according to low-normal (< 90 mg/dL), high-normal (90-99 mg/dL), prediabetes level 1 (100-109 mg/dL), prediabetes level 2 (110-125 mg/dL), type 2 diabetes (≥126 mg/dL) and type 2 diabetes on anti-diabetic medications.
The investigators identified 11,429 new cases of pancreatic cancer. They found that the risk for pancreatic cancer increased continuously with elevating fasting glucose levels. The 5-year cumulative incidence rates (per 100,000) were 32 for low-normal, 41 for high-normal, 50 for prediabetes level 1, 64 for prediabetes level 2, 75 for type 2 diabetes and 121 for patients prescribed anti-diabetes medications. The incidence of pancreatic cancer increased significantly with increasing fasting blood glucose levels even after adjusting for age, sex, smoking, drinking, exercise, body mass index and diabetes duration.
In analyses investigating the relationship between the diabetes duration and pancreatic cancer, the team observed a J-shaped association. There was no significant difference in the incidence of pancreatic cancer between the patients who received insulin and those who did not among populations treated with anti-diabetic medications.
Cheol-Young Park, MD, PhD, an Endocrinologist and senior author of the study, said, “Diabetes is one of the established risk factors for pancreatic cancer. When we evaluated the pancreatic cancer incidence according to fasting glucose levels using a national cohort database, we found the number of pancreatic cancer cases rose as fasting glucose levels increased. This was true in people who had diabetes as well as those who did not.” The study was published on July 24, 2019, in The Journal of Clinical Endocrinology & Metabolism.
Related Links:
Kangbuk Samsung Hospital
The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It makes enzymes that help digestion and hormones that control blood-sugar levels. Pancreatic cancer’s exact causes are not well understood. About 5% to 10% of pancreatic cancers are considered familial or hereditary. Most pancreatic cancer happens randomly or is caused by things such as smoking, obesity and age.
A team of scientists associated with Kangbuk Samsung Hospital (Seoul, Korea) analyzed data from 25.4 million patients who participated in a health examination between 2009 and 2013, using data from the National Health Insurance Service. They evaluated pancreatic cancer incidence rates according to fasting glucose level. Cumulative incidence rate for pancreatic cancer was calculated after grouping patients according to low-normal (< 90 mg/dL), high-normal (90-99 mg/dL), prediabetes level 1 (100-109 mg/dL), prediabetes level 2 (110-125 mg/dL), type 2 diabetes (≥126 mg/dL) and type 2 diabetes on anti-diabetic medications.
The investigators identified 11,429 new cases of pancreatic cancer. They found that the risk for pancreatic cancer increased continuously with elevating fasting glucose levels. The 5-year cumulative incidence rates (per 100,000) were 32 for low-normal, 41 for high-normal, 50 for prediabetes level 1, 64 for prediabetes level 2, 75 for type 2 diabetes and 121 for patients prescribed anti-diabetes medications. The incidence of pancreatic cancer increased significantly with increasing fasting blood glucose levels even after adjusting for age, sex, smoking, drinking, exercise, body mass index and diabetes duration.
In analyses investigating the relationship between the diabetes duration and pancreatic cancer, the team observed a J-shaped association. There was no significant difference in the incidence of pancreatic cancer between the patients who received insulin and those who did not among populations treated with anti-diabetic medications.
Cheol-Young Park, MD, PhD, an Endocrinologist and senior author of the study, said, “Diabetes is one of the established risk factors for pancreatic cancer. When we evaluated the pancreatic cancer incidence according to fasting glucose levels using a national cohort database, we found the number of pancreatic cancer cases rose as fasting glucose levels increased. This was true in people who had diabetes as well as those who did not.” The study was published on July 24, 2019, in The Journal of Clinical Endocrinology & Metabolism.
Related Links:
Kangbuk Samsung Hospital
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines